Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2011 Oct;16(5):533-8.
doi: 10.1007/s10147-011-0224-4. Epub 2011 Mar 23.

Combination therapy consisting of gemcitabine, carboplatin, and docetaxel as an active treatment for advanced urothelial carcinoma

Hiroshi Tsuruta  1 , Takamitsu Inoue, Shintaro Narita, Yohei Horikawa, Mitsuru Saito, Takashi Obara, Kazuyuki Numakura, Shinya Maita, Shigeru Satoh, Norihiko Tsuchiya, Tomonori Habuchi
Affiliations
Clinical Trial

Combination therapy consisting of gemcitabine, carboplatin, and docetaxel as an active treatment for advanced urothelial carcinoma

Hiroshi Tsuruta et al. Int J Clin Oncol. 2011 Oct.

Abstract

Background: To evaluate the efficacy and toxicity of a combination chemotherapy consisting of gemcitabine, carboplatin, and docetaxel (GCD) in patients with advanced urothelial carcinoma (UC) as a phase II trial.

Materials and methods: Patients with metastatic or locally advanced unresectable UC were eligible for this trial. All enrolled patients were considered to be "unfit" for cisplatin-based chemotherapy, or to have methotrexate, vinblastine, doxorubicin, cisplatin (MVAC)-refractory UC. The chemotherapy regimen consisted of gemcitabine 1000 mg/m(2) on days 1 and 8, and carboplatin (with a target area under the curve of 5) and docetaxel 70 mg/m(2) on day 1; this was repeated every 21 days.

Results: Thirty-five patients were enrolled, with a median age of 68 years. A total of 89 cycles were administered (median, 2 cycles). Major toxicities were Grade 3/4 neutropenia in 28 (80.0%) patients and Grade 3/4 thrombocytopenia in 18 (51.5%). An objective response rate (ORR) was 11 of 21 patients (52.4%), including a complete response in 1 (4.8%). The median overall survival (OS) was 13.1 months (1-year survival rate, 60%) and the median progression-free survival (PFS) was 5.0 months. Among 16 patients who had previously received MVAC, the ORR, the median PFS, the median OS and 1-year survival rate was 56.3%, 5.0 months, 12.6 months and 54%, respectively.

Conclusions: GCD chemotherapy is active and well tolerated as a first- or second-line therapy for patients with advanced UC. Response rate, duration and survival did not differ between those with and without a history of MVAC treatment.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Br J Cancer. 1998 Aug;78(3):370-4 - PubMed
    1. Cancer. 2001 Dec 15;92(12):2993-8 - PubMed
    1. J Clin Oncol. 2001 May 1;19(9):2527-33 - PubMed
    1. Eur J Cancer. 1998 Jul;34(8):1208-12 - PubMed
    1. Int J Urol. 2007 Sep;14(9):828-32 - PubMed

Publication types

MeSH terms

Supplementary concepts

LinkOut - more resources